AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
Read how SAGA Diagnostics’ AACR 2026 Pathlight data could reshape ctDNA monitoring in metastatic breast and ovarian cancer.
What SurGenTec’s TiLink navigation clearance means for surgeons using minimally invasive SI joint fusion systems
SurGenTec won FDA 510(k) clearance for TiLink navigation instruments. Read what this means for SI joint fusion adoption, workflow, and competition.
Can Covalon Technologies convert IV contamination education into adoption of VALGuard and CovaClear?
Covalon Technologies is gaining momentum in vascular access and wound care. Read why its latest milestones could shape medtech growth next.
CareDx divests Lab Products for $170m as core transplant diagnostics gains momentum
CareDx is selling its Lab Products business for $170 million. Read what the deal means for transplant diagnostics, growth focus, and execution risk.
Can TECNIS PureSee help Johnson & Johnson win the next phase of premium cataract surgery?
Johnson & Johnson’s TECNIS PureSee data could reshape premium cataract surgery. Read what the ASCRS 2026 findings may change next.
Plus Therapeutics reimbursement push gains traction as AMA grants CNSide a dedicated PLA code
Plus Therapeutics has won an AMA PLA code for CNSide. Read why this reimbursement milestone could shape adoption, coverage, and diagnostic growth.
Why Miracell’s SMART M-CELL FDA clearance could reshape the PRP and BMAC device market
Miracell has won FDA 510(k) clearance for SMART M-CELL. Read what it changes for PRP, BMAC, adoption, and regenerative medicine competition.
Can Junction’s GRAIL tie-up do what clinical data alone could not for Galleri adoption?
Junction and GRAIL are expanding Galleri access, but can workflow integration overcome regulatory, reimbursement, and adoption hurdles? Read more.
Could RenovoRx be building a stronger medtech oncology moat through global patent expansion?
Could RenovoRx’s Japan patent strengthen the RenovoCath oncology moat? Read the full PDN analysis on commercial risks, adoption, and global expansion.
How Biora Therapeutics’ BioJet platform may reshape needle-free delivery for peptides and antibodies
How Biora Therapeutics’ BioJet may reshape needle-free delivery for peptides and antibodies. Read the full PDN analysis on what changes next.